XML 48 R28.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue Recognition (Tables) | 9 Months Ended
--- | ---
Sep. 26, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | We generated net sales in the following geographic locations(1) (in millions):
| Three Months Ended |  | Nine Months Ended
| September 26, 2020 |  | September 28, 2019 |  | September 26, 2020 |  | September 28, 2019
U.S. | $ | 820.8 |  |  | $ | 785.9 |  |  | $ | 2,571.1 |  |  | $ | 2,323.2 |
Europe(2) | 326.6 |  |  | 334.6 |  |  | 1,011.0 |  |  | 991.3 |
All other countries(3) | 66.3 |  |  | 70.6 |  |  | 191.7 |  |  | 200.1 |
Total net sales | $ | 1,213.7 |  |  | $ | 1,191.1 |  |  | $ | 3,773.8 |  |  | $ | 3,514.6 |
(1) Derived from the location of the entity that sells to a third party. (2) Includes Ireland net sales of $10.8 million and $22.3 million for the three and nine months ended September 26, 2020, respectively, and $5.2 million and $17.3 million for the three and nine months ended September 28, 2019, respectively. (3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada. Product Category We re-aligned our product categories in our CSCA and CSCI segments as of December 31, 2019. The re-alignment standardizes our categories and product level detail to provide consistency. This transformative step will optimize the way in which management reports and evaluates our business. The following is a summary of our net sales by category (in millions); the comparative periods reflect the product category re-alignment:
| Three Months Ended |  | Nine Months Ended
| September 26, 2020 |  | September 28, 2019 |  | September 26, 2020 |  | September 28, 2019
CSCA(1) |  |  |  |  |  |  |
Upper respiratory | $ | 114.2 |  |  | $ | 123.4 |  |  | $ | 385.5 |  |  | $ | 377.4 |
Digestive health | 107.1 |  |  | 85.0 |  |  | 326.1 |  |  | 293.6 |
Pain and sleep-aids | 100.6 |  |  | 89.4 |  |  | 318.7 |  |  | 272.0 |
Nutrition | 100.1 |  |  | 97.1 |  |  | 290.9 |  |  | 282.6 |
Healthy lifestyle | 86.1 |  |  | 87.9 |  |  | 253.4 |  |  | 250.0 |
Oral self-care | 81.1 |  |  | 54.2 |  |  | 199.6 |  |  | 54.2 |
Skincare and personal hygiene | 49.2 |  |  | 45.4 |  |  | 138.8 |  |  | 136.7 |
Vitamins, minerals, and supplements | 6.3 |  |  | 6.2 |  |  | 19.1 |  |  | 18.7 |
Animal health | — |  |  | 1.8 |  |  | — |  |  | 43.7 |
Other CSCA(2) | 19.3 |  |  | 22.9 |  |  | 60.1 |  |  | 48.3 |
Total CSCA | 664.0 |  |  | 613.3 |  |  | 1,992.2 |  |  | 1,777.2 |
CSCI |  |  |  |  |  |  |
Skincare and personal hygiene | 83.1 |  |  | 88.9 |  |  | 275.4 |  |  | 296.5 |
Upper respiratory | 62.3 |  |  | 72.1 |  |  | 191.9 |  |  | 193.9 |
Vitamins, minerals, and supplements | 52.9 |  |  | 46.2 |  |  | 139.9 |  |  | 133.1 |
Pain and sleep-aids | 49.0 |  |  | 40.5 |  |  | 136.0 |  |  | 120.3 |
Healthy lifestyle | 40.6 |  |  | 38.2 |  |  | 124.7 |  |  | 134.2 |
Oral self-care | 25.2 |  |  | 24.3 |  |  | 68.8 |  |  | 27.7 |
Digestive health | 6.8 |  |  | 5.3 |  |  | 17.9 |  |  | 19.3 |
Other CSCI(3) | 19.1 |  |  | 32.0 |  |  | 88.2 |  |  | 100.8 |
Total CSCI | 339.0 |  |  | 347.5 |  |  | 1,042.8 |  |  | 1,025.8 |
RX | 210.7 |  |  | 230.3 |  |  | 738.8 |  |  | 711.6 |
Total net sales | $ | 1,213.7 |  |  | $ | 1,191.1 |  |  | $ | 3,773.8 |  |  | $ | 3,514.6 |
(1) Includes net sales from our OTC contract manufacturing business.
(2) | Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3) Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
Contract with Customer Balances | The following table provides information about contract assets from contracts with customers (in millions):
| Balance Sheet Location |  | September 26, 2020 |  | December 31, 2019
Short-term contract assets | Prepaid expenses and other current assets |  | $ | 21.2 |  |  | $ | 26.3 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration